A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer - Azaro, Analia; Rodon, Jordi; Calles, Antonio; Braña, Irene; Hidalgo, Manuel; Lopez-Casas, Pedro P.; Munoz, Manuel; Westwood, Paul; Miller, Joel; Moser, Brian A.; Ohnmacht, Ute; Bumgardner, William; et al. (Investigational new drugs, 2015)
Keywords: Adult; Aged; AKT protein; Alanine; Alanine transaminase; Anemia; Animals; Anticancer properties; Antineoplastic Agents - adverse effects; Antineoplastic Agents - pharmacokinetics; Antineoplastic Agents - therapeutic use; Antitumor activity; Aspartate aminotransferase; Biopsy; Cancer; Cancer therapies; Cell cycle; Cell growth; Constipation; Diarrhea; Drug dosages; Enzyme inhibitors; Epidermis; Female; Health services; Humans; International; Kinases; Male; Medical research; Medicine; Medicine & Public Health; Metabolites; Metastases; Metastasis; Mice, Nude; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Staging; Neoplasms - drug therapy; Neoplasms - enzymology; Neoplasms - pathology; Neutropenia; Oncology; p70 S6 kinase; Patients; Pharmaceutical industry; Pharmacodynamics; Pharmacokinetics; Pharmacology; Pharmacology/Toxicology; Phase I Studies; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - pharmacokinetics; Protein Kinase Inhibitors - therapeutic use; Proteins; Proto-Oncogene Proteins c-akt - antagonists & inhibitors; Proto-Oncogene Proteins c-akt - metabolism; R&D; Regulatory approval; Research & development; Ribosomal Protein S6 Kinases, 70-kDa - antagonists & inhibitors; Ribosomal Protein S6 Kinases, 70-kDa - metabolism; Skin; Studies; Toxicity; Transaminases; Tumors; Xenograft Model Antitumor Assays; Young Adult; γ-Glutamyltransferase; Spain; PI3K/Akt/mTOR signaling pathway; mTOR; p70 S6 kinase (p70S6K); Akt; LY2780301; Cancer